Christopher Yea - 21 Feb 2025 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Issuer symbol
KALV
Transactions as of
21 Feb 2025
Net transactions value
-$19,218
Form type
4
Filing time
25 Feb 2025, 20:36:14 UTC
Previous filing
19 Feb 2025
Next filing
20 May 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALV Common Stock Options Exercise +3,125 +3.4% 95,870 22 Feb 2025 Direct F1
transaction KALV Common Stock Sale $19,218 -1,918 -2% $10.02 93,952 24 Feb 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Restricted Stock Unit Award $0 +60,000 $0.000000 60,000 21 Feb 2025 Common Stock 60,000 Direct F1, F3
transaction KALV Restricted Stock Unit Options Exercise $0 -3,125 -7.1% $0.000000 40,625 22 Feb 2025 Common Stock 3,125 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3 1/16th of the total number of shares underlying the RSUs shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate.